Melanin produced by yeast Nadsoniella nigra strain X-1 lead to significant reduction of steatosis, lobular inflammation and ballooning degeneration, according to NAFLD activity score (NAS), in liver of rats with monosodium glutamate (MSG) induced obesity. These histological changes were associated with substantial decrease of TNF-α expression in sinusoid cells that prevented NF-kB activation in hepatocytes.
BallK., MishraG., CrawfordD. (2002) Which aspects of socioeconomic status are related to obesity among men and women?International journal of obesity and related metabolic disorders, 26, 559–565.
2.
EpsteinL.H., GordyC.C., RaynorH.A., BeddomeM., KilanowskiC.K., PaluchR. (2001) Increasing fruit and vegetable intake and decreasing fat and sugar intake in families at risk for childhood obesity. Obesity Research, 9, 171–178.
3.
KobyliakN., VirchenkoO., FalalyeyevaT. (2016) Pathophysiological role of host microbiota in the development of obesity. Nutrition Journal, 15, 43.
4.
TsaiA.G., WilliamsonD.F., GlickH.A. (2011) Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obesity reviews: an official journal of the International Association for the Study of Obesity, 12, 50–61.
5.
AnguloP., LindorK.D. (2002) Non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 17, 186–190.
6.
FarrellG.C., LarterC.Z. (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 43, 99–112.
7.
KobyliakN., AbenavoliL. (2014) The role of liver biopsy to assess non-alcoholic fatty liver disease. Reviews on Recent Clinical Trials, 9, 159–169.
8.
MussoG., GambinoR., CassaderM., PaganoG. (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 43, 617–649.
9.
GeffkenD.F., CushmanM., BurkeG.L., PolakJ.F., SakkinenP.A., TracyR.P. (2001) Association between physical activity and markers of inflammation in a healthy elderly population. American journal of Epidemiology, 153, 242–250.
10.
KobyliakT.FalalyeyevaP.BodnarT., Beregova, (2017) Probiotics supplemented with omega-3 fatty acids are more effective for hepatic steatosis reduction in an animal model of obesity. Probiotics and Antimicrobial Proteins, 9, 123–130.
11.
KobyliakN., FalalyeyevaT., BoykoN., TsyryukO., BeregovaT., OstapchenkoL. (2018) Probiotics and nutraceuticals as a new frontier in obesity prevention and management. Diabetes Research and Clinical Practice, 141, 190–199.
12.
AbenavoliL., MilicN., Di RenzoL., PrevedenT., Medić-StojanoskaM., De LorenzoA. (2016) Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 22, 7006–7016.
13.
KobyliakN., FalalyeyevaT., VirchenkoO., MykhalchyshynG., BodnarP., SpivakM., YankovskyD., BeregovaT., OstapchenkoL. (2016) Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention. BMC Gastroenterology, 16, 34.
14.
KobyliakN., AbenavoliL., MykhalchyshynG., KononenkoL., BoccutoL., KyriienkoD., DynnykO. (2018) A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial. Journal of Gastrointestinal and Liver Diseases, 27, 41–49.
15.
MohsenM., SyedaH. (2010) Dietary Polyphenols and Obesity. Nutrients, 2, 737–751.
16.
WangS., Moustaid-MoussaN., ChenL., MoH., ShastriA., SuR., BapatP., KwunI., ShenC. (2014) Novel insights of dietary polyphenols and obesity. The Journal of Nutritional Biochemistry, 25, 1–18.
17.
FarhatG., DrummondS., Al DujailiE.A.S. (2017) Polyphenols and Their Role in Obesity Management: A Systematic Review of Randomized Clinical Trials. Phytotherapy Research, 31, 1005–1018.
18.
KalupahanaN.S., Moustaid-MoussaN., ClaycombeK.J. (2012) Immunity as a link between obesity and insulin resistance. Molecular aspects of medicine, 33, 26–34.
19.
BelemetsN., KobyliakN., VirchenkoO., FalalyeyevaT., TsyryukO., BodnarP., SavchukO., GalenovaT., CaprndaM., RodrigoL., SkladanyL., DelevD., OpatrilovaR., KruzliakP., BeregovaT., OstapchenkoL. (2017) Effects of polyphenol compounds melanin on NAFLD/NASH prevention. Biomedicine and Pharmacotherapy, 88, 267–276.
20.
PettaS., GastaldelliA., RebelosE., BugianesiE., MessaP., MieleL., Svegliati-BaroniG., ValentiL., BoninoF. (2016) Pathophysiology of non alcoholic fatty liver disease. International Journal of Molecular Sciences, 2016, 17.
21.
LewisJ.R., MohantyS.R. (2010) Nonalcoholic fatty liver disease: A review and update. Digestive Diseases and Sciences, 55, 560–578.
22.
CaiD., YuanM., FrantzD.F., MelendezP.A., HansenL., LeeJ., ShoelsonS.E. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nature Medicine, 11, 183–190.
23.
GaoH.Y., HuangJ., WangH.Y., DuX.W., ChengS.M., HanY., WangL.F., LiG.Y., WangJ.H. (2013) Protective effect of Zhuyeqing liquor, a Chinese traditional health liquor, on acute alcohol-induced liver injury in mice. Journal of Inflammation, 10, 30.
24.
KobyliakN., AbenavoliL., FalalyeyevaT., BeregovaT. (2018) Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease. Annals of Hepatology, 17, 153–161.
25.
KobyliakN., FalalyeyevaT., BeregovaT., SpivakM. (2017) Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition. Endokrynologia Polska, 68, 659–667.
26.
KondroM., MykhalchyshynG., BodnarP., KobyliakN., FalalyeyevaT. (2013) Metabolic profile and morpho-functional state of the liver in rats with glutamate-induced obesity. Current Issues in Pharmacy and Medical Sciences, 26, 379–381.
27.
PermyakovaN., ZheltonozhskayaT., BeregovaT., KlymchukD., FalalyeyevaT. (2016) Micellar nanocarriers for anticancer drug melanin. Molecular Crystals and Liquid Crystals, 640, 122–133.
